XM does not provide services to residents of the United States of America.

1 drugs compound snack makers' woes



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>LIVE MARKETS-GLP-1 drugs compound snack makers' woes</title></head><body>

Major U.S. indexes modestly red; Dow off ~0.4%

Cons disc weakest S&P sector; Energy leads gainers

Euro STOXX 600 index up ~0.2%

Dollar ~flat; gold slips; crude, bitcoin both up >2

U.S. 10-Year Treasury yield rises to ~4.03%

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

GLP-1 DRUGS COMPOUND SNACK MAKERS' WOES

Packaged food makers such as Hershey HSY.N face a greater threat from weight-loss drugs than anticipated, with usage on the rise, helped by online health platforms offering compounded GLP-1 weight-loss injections, analysts at Bernstein noted.

With branded GLP-1 drugs from Novo Nordisk and Eli Lilly short in supply, demand for custom-made weight-loss treatments created by combining, mixing, or altering drug ingredients has soared, and could be reaching a larger number of GLP-1 patients than captured in official data, Bernstein said.

Patterns of food consumption pointed to weakness for sweet snacks and fast food, and strength for healthier items such as soup, cottage cheese and Greek yogurt, which are consistent with the eating habits of GLP-1 patients, Bernstein noted.

The brokerage downgraded chocolate maker Hershey to "market-perform," on risks that volume recovery may be more sluggish than expected due to GLP-1 headwinds, while raising soup maker Campbell to "outperform."

U.S. telehealth company Hims & Hers Health HIMS.N began selling compounded GLP-1 medications in May. The company said in August, that the program had about 100,000 subscribers.

Vitamin Shoppe also provided access to weight-loss medication through its telehealth service, while retailer Costco Wholesale offered its roughly 130 million members access to weight-loss programs this year.

The S&P 500 Packaged Foods & Meats .SPLRCFOOD has risen 2.6% so far this year, lagging a 14% rise in the consumer staples index .SPLRCS, and a 20% rise in the S&P 500 .SPX index.


(Juveria Tabassum)

*****



FOR MONDAY'S EARLIER LIVE MARKETS POSTS:


PAYROLLS HANGOVER: GEOPOLITICS, UNCERTAINTIES WEIGH ON RISK APPETITE - CLICK HERE


CRUDE OIL FUTURES HEATING UP ON THE CHARTS - CLICK HERE


U.S. ELECTION: PREPARE FOR UNCERTAINTY AND VOLATILITY - CLICK HERE


REAL ESTATE TOUR: WARMING UP TO OFFICES - CLICK HERE


RISING YIELDS WEIGH, BANKS EDGE UP - CLICK HERE


EUROPEAN FUTURES INCH HIGHER - CLICK HERE


US 'NO LANDING' SCENARIO LIFTS MARKETS - CLICK HERE



</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.